<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>MORRHUATE SODIUM- morrhuate sodium injection, solution </strong><br>American Regent, Inc.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1><span class="Bold">MORRHUATE SODIUM INJECTION, USP
</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_772430f1-b471-4be9-8b4d-b4c12f63ae47"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_995765ff-9c66-412c-bc9c-47a19b6ec3bc"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION </span></h1>
<p class="First">Morrhuate Sodium Injection, USP, is a mixture of the sodium salts of the saturated and unsaturated fatty acids of Cod Liver Oil. Morrhuate Sodium Injection, USP is prepared by the saponification of selected Cod Liver Oils. Morrhuate Sodium occurs as a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellowish, granular powder with a slight fishy odor and is soluble in water and in alcohol.</p>
<p>Each mL contains: Morrhuate Sodium 50 mg, Benzyl Alcohol 2% (as a local anesthetic), Water for Injection q.s.  pH adjusted with Hydrochloric Acid and/or Sodium Hydroxide.</p>
<p>The pH of the injection is adjusted to approximately 9.5.</p>
<p>NOTE: PRODUCT MAY SHOW A SEPARATION OF A SOLID MATTER ON STANDING. DO NOT USE IF SUCH SOLID DOES NOT DISSOLVE COMPLETELY UPON WARMING.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_3c1d7bb2-05e1-451c-839e-cdf457a7bb1d"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">PHARMACOLOGY </span></h1>
<p class="First">Morrhuate Sodium, when injected into the vein, causes <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the intima and formation of a thrombus. This blood clot occludes the injected vein and fibrous tissue develops, resulting in the obliteration of the vein.</p>
<p><span class="Bold"><span class="Italics">USES</span></span>:</p>
<p>Morrhuate Sodium Injection is used for the obliteration of primary varicosed veins that consist of simple dilation with competent valves.</p>
<p>Sclerotherapy should not be used in patients with significant valvular or deep vein incompetence. (see <span class="Bold"><a href="#LINK_0f17347a-db6c-4097-acce-7472039756d8">CAUTIONS</a></span><span class="Bold">.</span>)</p>
<p>Although Morrhuate Sodium has been used as a sclerosing agent for the treatment of internal <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, there is no substantial evidence that the drug is useful for this purpose.</p>
<p>Most patients with symptomatic primary varicosed veins should be treated initially with compression stockings. If this treatment is inadequate, surgery may be required. Sclerosing agents may be useful as a supplement to venous ligation to obliterate residual varicosed veins or in patients who have conditions which increase the risk of surgery. However, many clinicians consider if sclerotherapy is not effective it may decrease the potential success of later surgery, should this be required.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0f17347a-db6c-4097-acce-7472039756d8"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">CAUTIONS: 
</span></h2>
<p class="First">Burning or cramping sensations indicate local reactions. <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> may result.  <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">Sloughing</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of tissue may occur with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> of the drug. Technique development is essential for optimal success in sclerotherapy, therefore the drug should be administered only by a physician familiar with proper injection technique. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may occur rarely. <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> has been reported.</p>
<p>Rarely, patients may have, or may develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Morrhuate Sodium, characterized by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> (i.e., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> may occur within a few minutes after injection of the drug and are most likely to occur when therapy is reinstituted after an interval of several weeks. Morrhuate Sodium should only be administered when adequate facilities, drugs (i.e., epinephrine, antihistamines, corticosteroids), and personnel are available for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_4c9310f1-8afc-44c2-b560-3f9eb9fc71c6"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Morrhuate Sodium is contraindicated in patients who have shown a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to the drug or to the fatty acids of cod liver oil.  Continued administration of the drug is contraindicated when an unusual local reaction at the injection site or a systemic reaction occurs.</p>
<p><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> induced by Morrhuate Sodium may extend into the deep venous system in patients with significant valvular incompetence, therefore, valvular competency, deep vein patency, and deep vein competency should be determined by angiography and/or by tests such as the Trendelenberg and Perthes before injection of sclerosing agents. The drug is contraindicated for obliterations of superficial veins in patients with persistent occlusion of the deep veins. Morrhuate Sodium is also contraindicated in patients with acute <span class="product-label-link" type="condition" conceptid="442058" conceptname="Superficial thrombophlebitis in pregnancy and the puerperium">superficial thrombophlebitis</span>; underlying arterial disease; varicosities caused by abdominal and pelvic tumors, uncontrolled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, neoplasms, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, acute respiratory or skin disease; and in bedridden patients. Treatment with Morrhuate Sodium should be delayed in patients with acute local or systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (including infected <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>). Extensive therapy with the drug is inadvisable in patients who are severely debilitated or senile.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_79fc166e-c7db-40e9-9748-c28d01bad839"></a><a name="section-5"></a><p></p>
<h1>PREGNANCY: Pregnancy Category C:</h1>
<p class="First">Animal reproduction studies have not been performed. It is not known whether Morrhuate Sodium Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Use of Morrhuate Sodium in women of childbearing potential requires that anticipated benefits be weighed against the possible hazards.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_225f6b82-8d63-4c13-abac-2db3a11874b7"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">DOSAGE</span></h1>
<p class="First">Morrhuate Sodium is administered only by INTRAVENOUS injection. Care must be taken to avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>. (See <span class="Bold"><a href="#LINK_0f17347a-db6c-4097-acce-7472039756d8">CAUTIONS</a></span>.) Specialized references should be consulted for specific procedures and techniques of administration. When small veins are injected, or the injection solution is <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, or if solid matter has separated in the solution, the vial should be warmed by immersing in hot water. The solution should become clear on warming.  Only a clear solution should be used. Because the solution froths easily, a large bore needle should be used to fill the syringe. However, a small bore needle should be used for the injection.</p>
<p>To determine possible sensitivity to the drug, some clinicians recommend injection of 0.25 to 1 mL of 5% Morrhuate Sodium Injection into a <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicosity</span> 24 hours before administration of a large dose.</p>
<p>Dosage of Morrhuate Sodium depends on the size and degree of <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicosity</span>. The usual adult dose for obliteration of small or medium veins is 50 to 100 mg (1 to 2 mL of the 5% injection).  For large veins, 150 to 250 mg (3 to 5 mL of the injection) is used. The drug may be given as multiple injections at one time or in single doses.  Therapy may be repeated 5 to 7 day intervals, according to the patient's response. Following injection of Morrhuate Sodium, the vein promptly becomes hard and swollen for 2 to 4 inches, depending on the size and response of the vein. After 24 hours, the vein is hard and slightly tender to the touch (with little or no periphlebitis). The skin around the injection becomes light-bronze.  This color usually disappears shortly. An aching sensation and feeling of <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> usually occurs and lasts approximately 48 hours.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_70cbaf80-ecc5-494c-86fc-7cbe7665614d"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Morrhuate Sodium Injection, USP 50 mg/mL</p>
<p>NDC 0517-3065-01              30 mL Multiple Dose Vial              Individually Packaged</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_b2f69db8-28c3-4fd7-9722-2b5b13ec5841"></a><a name="section-7.1"></a><p></p>
<h2></h2>
<p class="First">Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).</p>
<p>IN3065<br>Rev. 8/13</p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span><span class="Bold">SHIRLEY, NY 11967</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_fda369e9-65e6-4c12-b2e2-b189c91bd9b6"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL </span></h1>
<p class="First"><span class="Bold"><span class="Underline">Container</span></span></p>
<p><span class="Bold">NDC 0517-3065-01</span></p>
<p><span class="Bold">MORRHUATE SODIUM<br></span>INJECTION, USP</p>
<p><span class="Bold">50 mg/mL</span> (5%)<br><br><span class="Bold">30 mL<br></span>MULTIPLE DOSE VIAL</p>
<p><span class="Bold">FOR IV USE ONLY</span></p>
<p><span class="Bold">CAUTION</span>: AVOID <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">EXTRAVASATION</span><br><span class="Bold"><br>Rx Only</span></p>
<p><span class="Bold">AMERICAN REGENT, INC</span>.<br>SHIRLEY, NY  11967</p>
<p> <img alt="Container" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9298b254-4311-46cd-9244-8651dd87417e&amp;name=morrhuate-sodium-1.jpg"> </p>
<p><span class="Bold"><span class="Underline">Carton</span><br></span><br><span class="Bold">NDC 0517-3065-01</span></p>
<p><span class="Bold">30 mL </span>MULTIPLE DOSE VIAL</p>
<p><span class="Bold">MORRHUATE SODIUM<br></span>INJECTION, USP</p>
<p><span class="Bold">50 mg/mL</span> (5%)</p>
<p><span class="Bold">FOR IV USE ONLY</span></p>
<p><span class="Bold">CAUTION</span>: AVOID <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">EXTRAVASATION</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">AMERICAN<br>REGENT, INC.</span><br>SHIRLEY, NY 11967</p>
<div class="Figure"><img alt="Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9298b254-4311-46cd-9244-8651dd87417e&amp;name=morrhuate-sodium-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MORRHUATE SODIUM 		
					</strong><br><span class="contentTableReg">morrhuate sodium injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-3065</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MORRHUATE SODIUM</strong> (MORRHUIC ACID) </td>
<td class="formItem">MORRHUATE SODIUM</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-3065-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Luitpold Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">002033710</td>
<td class="formItem">ANALYSIS(0517-3065), MANUFACTURE(0517-3065), STERILIZE(0517-3065)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b14ce76e-15ed-4c72-81fb-79d441245c19</div>
<div>Set id: 9298b254-4311-46cd-9244-8651dd87417e</div>
<div>Version: 3</div>
<div>Effective Time: 20140904</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
